Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

A. Huthmacher, Jessica; J. Meier, Juris; A. Nauck, Michael

doi:10.2337/dc20-0498

Public

Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

Published in Diabetes Care • Aug 11, 2020

Authors:

Jessica A. Huthmacher

Juris J. Meier

Michael A. Nauck

Abstract

PURPOSE To compare the efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin, in patients with type 2 diabetes. DATA SOURCES AND STUDY SELECTION Randomized controlled trials comparing the coadministration of s...

Subject

Medicine

Glucagon-like peptide 1 receptor

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!